Hypouricemic effect of allopurinol and the novel xanthine oxidase inhibitor TEI-6720 in chimpanzees

https://doi.org/10.1016/0014-2999(93)90033-EGet rights and content

Abstract

The hypouricemic effect of a newly synthesized xanthine oxidase / xanthine dehydrogenase inhibitor, TEI-6720, 2-(3-cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylic acid, was investigated and compared with that of allopurinol in male chimpanzees (n = 3). When allopurinol (10 mg/kg) was administered orally once a day for three consecutive days, it cumulatively reduced serum urate levels by 29.7, 50.1 and 60.2%, 24, 48 and 72 h, respectively, after the initial dose. This effect was dose dependent at doses of 3 and 10 mg/kg. At 3 mg/kg, the mean serum urate levels were 3.1, 2.4, 2.5 and 2.3 mg/dl before and 24, 48 and 72 h, respectively, after the initial dose. Animals treated with 10 mg/kg of allopurinol showed serum urate levels of 3.3, 2.3, 1.6 and 1.3 mg/dl, respectively. The urate-lowering effect of TEI-6720 was then comapred with that of allopurinol at a daily dose of 5 mg/kg (n = 3). Both compounds caused striking reductions in serum and urinary uric acid levels accompanied by an increase in urinary xanthine levels. These effects of TEI-6720 were more potent than those of allopurinol. TEI-6720 reduced serum urate levels by 55.9, 69.6 and 73.6%, 24, 48 and 72 h, respectively, after the first dose, whereas, the corresponding values after allopurinol were 28.1, 41.6 and 45.1%. These results suggest that the hypouricemic effect of TEI-6720 may be more potent than that of allopurinol in the treatment of hyperuricemia and gout, and that TEI-6720 may become an effective alternative drug.

References (9)

There are more references available in the full text version of this article.

Cited by (66)

  • Hyperuricemia Is an Independent Risk Factor for Erectile Dysfunction

    2016, Journal of Sexual Medicine
    Citation Excerpt :

    Febuxostat is a selective inhibitor of xanthine oxidase that reduces serum uric acid levels by inhibiting the transformation of hypoxanthine to xanthine and of xanthine to uric acid, and has no effect on other enzymes in purine metabolism. Febuxostat was more potent than allopurinol in inhibiting xanthine oxidase and decreasing serum uric acid levels in chimpanzees.22 In this study, there is no significant difference in body weight, level of serum testosterone, blood urea nitrogen, and creatinine among these groups, but the ICPmax/MAP in hyperuricemic rats is significantly less than that in other groups.

  • Trisubstituted thiophene analogues of 1-thiazolyl-2-pyrazoline, super oxidase inhibitors and free radical scavengers

    2013, Bioorganic and Medicinal Chemistry
    Citation Excerpt :

    Recently one of the nonpurine inhibitor, thiazole derivative, Febuxostat (7) was approved by the European Medicines Evaluation Agency (EMEA) and Food and Drug Administration (FDA), has attracted worldwide attention.25 Scholar review article by Raj Kumar et al extensively covered all patent survey for xanthine oxidase inhibitors including nonpurine analogues.26 Kavitha et al. reported substituted iminothiazoles as possible antioxidant agents (8).27

  • Novel thiazolo-pyrazolyl derivatives as xanthine oxidase inhibitors and free radical scavengers

    2012, International Journal of Biological Macromolecules
    Citation Excerpt :

    However use of purine analog leads to development of symptoms for Stevens–Johnson syndrome and DRESS (Drug Rash with Eosinophylia and Systemic Symptoms) [12,13] therefore extensive research has been done to report non purine analogs for XO inhibition. Recently one of the non purine inhibitor-Febuxostate (6)-that was approved by the European Medicines Evaluation Agency (EMEA) and Food and Drug Administration (FDA), has attracted worldwide attention [14]. Scholar review article by Raj Kumar et al. extensively covered all patent survey for xanthine oxidase inhibitors including non purine analogs [15].

  • Xanthine oxidase inhibitor treatment of hyperuricemia

    2012, Gout and Other Crystal Arthropathies
  • Xanthine oxidase inhibitor treatment of hyperuricemia

    2011, Gout and Other Crystal Arthropathies: Expert Consult: Online and Print
View all citing articles on Scopus
View full text